放疗联合顺铂和多西他赛治疗非小细胞肺癌的临床观察
-
摘要: 非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的70%~80%,放化疗联合治疗NSCLC能提高局部控制率和长期生存率。多西他赛作为新型抗肿瘤药物,对NSCLC有明显的辐射增敏作用。2005年1月至2008年12月,我们采用放疗加多西他赛、顺铂治疗Ⅲ期NSCLC 108例,并与顺铂、长春瑞滨方案序贯放化疗进行对比,现报告如下。
-
[1] 孙燕.赵平.临床肿瘤学进展.北京:中国协和医科大学出版社,2005:183-192
[2] Schild SE,Stella PJ,Geyer SM,et al.Phase Ⅲ trail comparing chemotherapy plus once-daily or twice-daily radiotherapy in stageⅢ non-small-cell lung cancer.Int J Radial Oncol Biol Phys,2002,54(2):370-378. [3] Lara PN Jr,Goldberg Z,Davies A,et al.Concurrent chemoradiation strategies in the management of unresectable stageⅢ non-small-cell lung cancer.Clin Lung Cancer,2002,3 Suppl 2:S42-S48. [4] Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,2002,346(2):92-98. [5] Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Meal,2006,355(24):2542-2550.
点击查看大图
计量
- 文章访问数: 1847
- HTML全文浏览量: 173
- PDF下载量: 2